The FDA just dropped new guidance on how drugmakers can develop, distribute, and label apps that accompany prescription medicines. The policy clarifies when these apps need FDA submission, when they should appear in drug labeling, and how patient-facing content will be regulated. The goal: cut through regulatory uncertainty while keeping safety standards intact.
The FDA has issued new guidance to help drug companies and tech developers navigate the increasingly complex world of prescription drug companion apps. As digital health tools become more common alongside traditional medicines, the agency is drawing clearer lines around what needs regulatory attention — and what doesn't.
The guidance covers three key areas: when app content must be submitted to the FDA, when apps should be referenced in a drug's prescribing information, and what details companies need to provide to regulators. Apps tied to medical devices — like software paired with an asthma inhaler — should generally be included in the drug's label. Standalone apps offering symptom tracking, reminders, or coaching only need to appear in the label if they're essential for safe and effective use or provide meaningful clinical benefit.
Key Takeaways:
Why it matters: With digital health tools proliferating fast, this guidance gives drugmakers and developers a clearer regulatory roadmap — reducing uncertainty while ensuring that app-based patient interactions meet the same safety and transparency standards as traditional drug promotion.
